Search Results
5-year follow-up results of CLL14: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil in CLL
CLL14 trial: obinutuzumab + venetoclax vs obinutuzumab + chlorambucil
Six-year update from CLL14: fixed-duration venetoclax + obinutuzumab for previously untreated CLL
6-year results of CLL14: venetoclax-obinutuzumab for previously untreated CLL
CLL14: Venetoclax plus obinutuzumab for CLL
CLL14: Venetoclax plus obinutuzumab in untreated CLL
Venetoclax and obinutuzumab combination therapy for CLL
Four-year follow-up from a Phase II study of obinutuzumab, ibrutinib, and venetoclax in CLL
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
5-year update of ELEVATE CLL TN
Dr. Gerson on Venetoclax/Obinutuzumab Combination in CLL
Undetectable MRD after obinutuzumab plus venetoclax in CLL
